New study aims to fill gap in breast cancer treatment for elderly

NCT ID NCT07399808

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how older women (70 years and above) with breast cancer handle CDK4/6 inhibitors, a common targeted therapy. Researchers will track side effects and compare them to younger patients. The goal is to gather real-world data to improve treatment decisions for this often-underrepresented group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CDK4/6 inhibitors
What this could lead to: If successful, this study could help doctors better understand how to safely use CDK4/6 inhibitors in older breast cancer patients, leading to more personalized treatment guidelines.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not change practice immediately, and the small size (100 patients) limits how widely findings can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER OLD AGE

Contacts and locations

Locations

Fondazione IRCCS Policlinico San Matteo di Pavia
RECRUITING

Pavia, Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.